Search Results
Jan 14, 2026, 17:31 ET House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight
Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country, effective July 3.In February 2025, the US FDA approved ALK's ODACTRA tablet for use in young children with HDM allergy. ODACTRA is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis,
More news about: DelveInsight Business Research, LLP
Dec 12, 2025, 16:38 ET Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL
Avadel Pharmaceuticals plc (NasdaqGM: AVDL) to Alkermes plc (NasdaqGS: ALKS). Under the terms of the proposed transaction, shareholders of Avadel will receive $18.50 per share, plus a non-transferable contingent value right entitling
More news about: Kahn Swick & Foti, LLC
Nov 19, 2025, 06:00 ET Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached agreement on the
More news about: Alkermes plc
Nov 14, 2025, 07:51 ET Alkermes Response to Avadel Announcement
DUBLIN, Nov. 14, 2025 /PRNewswire/ -- Alkermes plc ("Alkermes") (Nasdaq: ALKS) notes the announcement made by Avadel Pharmaceuticals plc ("Avadel") regarding a possible offer by H. Lundbeck A/S ("Lundbeck") to acquire all the issued
More news about: Alkermes plc
Nov 14, 2025, 07:45 ET Alkermes Response to Avadel Announcement
DUBLIN, Nov. 14, 2025 /PRNewswire/ -- Alkermes plc ("Alkermes") (Nasdaq: ALKS) notes the announcement made by Avadel Pharmaceuticals plc ("Avadel") regarding a possible offer by H. Lundbeck A/S ("Lundbeck") to acquire all the issued
More news about: Alkermes plc
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, formerly referred to as ALKS 2680, is the company's novel, investigational, oral,
More news about: Alkermes plc
Nov 12, 2025, 07:30 ET Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, formerly referred to as ALKS 2680, is the company's novel, investigational, oral,
More news about: Alkermes plc
Nov 06, 2025, 16:00 ET Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare
More news about: Alkermes plc
Nov 05, 2025, 09:00 ET FORM 8.1(a) & (b) (Opening Position Disclosure)
DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL
More news about: Alkermes plc
Oct 28, 2025, 07:00 ET Alkermes plc Reports Third Quarter 2025 Financial Results
Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong
More news about: Alkermes plc
Oct 22, 2025, 07:00 ET Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
capabilities of the combined organization will support a broad development strategy for Alkermes' portfolio of orexin 2 receptor agonists, including ALKS 4510 and ALKS 7290, which are currently in phase 1 studies. In addition, the combined resources will support the advancement of clinical studies to support
More news about: Alkermes plc; Avadel Pharmaceuticals plc
Oct 20, 2025, 16:00 ET Alkermes to Report Third Quarter Financial Results on October 28, 2025
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter
More news about: Alkermes plc
Sep 12, 2025, 09:00 ET Alkermes Appoints Joshua Reed as Chief Financial Officer
Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday,
More news about: Alkermes plc
Sep 11, 2025, 07:00 ET Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
DUBLIN, Sept. 11, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Monday,
More news about: Alkermes plc